Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2022 Dec 14;41(30):5877–5878. doi: 10.1002/sim.9597

Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process

Sylwia Bujkiewicz 1
PMCID: PMC10117606  PMID: 36515222

I would like to report an erratum to the paper titled 'Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process' by Bujkiewicz, Thompson, Riley and Abrams, Statistics in Medicine. 1

Unstructured covariance model

There were a couple of errors in the formulae (11) for the relationships of the parameters of the trivariate between‐study model (10) with the elements of the covariance matrix T in Eq (2). The correct formulae for the conditional variance ψ32 and the coefficients λ31 and λ32 should read:

ψ32=τ32λ312τ12λ322τ222λ31λ32λ21τ12,
λ31=τ3ρb13ρb12ρb23τ11ρb122,λ32=τ3ρb23ρb12ρb13τ21ρb122

The same formulae should be replaced in equations (21) and (22), where also the formulae corresponding to the N‐dimensional case should read:

ψN2=τN2i=1N1λNi2τi221i<jN1λNiλNjCov(μi,μj)λNQ=ρbQNτQτNP=1,PQN1λNPCov(μP,μQ)/τQ2

The corresponding parts of the bugs code in the online supplement should read:

gammaD.sq<‐pow(sd.dis,2) ‐ pow(lambdaD1,2)*pow(sd.mri,2) ‐ pow(lambdaD2,2)*pow(sd.rel,2) ‐2*lambdaD1*lambdaD2*lambdaR1*pow(sd.mri,2)

lambdaD1<‐(corr.dis.mri‐corr.rel.mri*corr.dis.rel)*sd.dis/sd.mri/(1‐pow(corr.rel.mri,2))

lambdaD2<‐(corr.dis.rel‐corr.rel.mri*corr.dis.mri)*sd.dis/sd.rel/(1‐pow(corr.rel.mri,2))

This error had a negligible impact on the results. We are grateful to Dr Georgios Nikolaidis and Anastasios Tasoulas at IQVIA for bringing this to our attention.

Structured covariance model

We also note that there was a typographical error in the online supplement; in the bugs code for the structured model corresponding to ψ32 in eq. (13) (with no impact on any results). The correct line in the code should read:

gammaD.sq<‐pow(sd.dis,2) ‐ pow(lambdaD2,2)*pow(sd.rel,2)

We thank Valentine Barboux (at the time at Servier) for bringing this to our attention.

DATA AVAILABILITY STATEMENT

The data are included in Table 1 of the original manuscript: Stat Med 2016, v35, 1063–1089.

REFERENCE

  • 1. Bujkiewicz S, Thompson JR, Riley RD, Abrams KR. Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process. Stat Med. 2016;35(7):1063‐1089. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data are included in Table 1 of the original manuscript: Stat Med 2016, v35, 1063–1089.


Articles from Statistics in Medicine are provided here courtesy of Wiley

RESOURCES